Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123938) titled 'A Phase I, open-label, dose-escalation clinical study evaluating the safety and tolerability of macrophage-derived exosomes reprogrammed by cellular mechanics for intratumoral administration in subjects with advanced solid tumors' on May 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Advanced Solid Tumors
Intervention:
Low-dose group:Intratumoral injection of mechanically reprogrammed macrophage-derived exosomesn (1x10^10 exosomes/dose), once every 2 weeks for 4 doses.
Medium-dose group:Intratumoral injection of mechanically re...